Opinion|Videos|May 9, 2025
Risk Factors of CHE
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how risk factors for chronic hand eczema (CHE) include atopic dermatitis, filaggrin mutations, contact allergies, environmental conditions, and occupational exposures, with hand eczema being the most common occupational skin disease.
Advertisement
Video content above is prompted by the following:
Risk Factors of CHE
Key Themes:
- Environmental risk factors: Occupational exposures, weather conditions, decreased indoor humidity, and tobacco use.
- Physiological risk factors: Atopic dermatitis history, early onset of hand eczema, filaggrin mutations, and contact allergies.
- Occupational considerations: Highest risk industries include hairdressing, health care, food service, cleaning, and manufacturing, with CHE being the most common occupational skin disease.
Notable Insights:
Dr Chovatiya highlighted the difficulty in risk factor modification: "Even though sometimes we can do really good detective work...the actual implementation of changes to practically help people on a day-to-day basis can be very, very difficult."
Advertisement
Related to this article
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
3
When Innovation Builds Clinical Confidence: Evaluating Treatment Options in Hemophilia A
4
The HCPFive: Top News for Healthcare Providers from the Week of 09/13
5